Key result
Drug-eluting coronary stents are associated with disturbing new findings regarding the risk of late thrombosis, fueling controversy over their safety despite preventing restenosis.
Why the study?
Do drug-eluting coronary stents increase the risk of late thrombosis despite preventing restenosis?
Do drug-eluting coronary stents increase the risk of late thrombosis despite preventing restenosis?
Answers are grounded in this paper and cite their sources.
Discusses the controversy and emerging concerns regarding late thrombosis risk associated with drug-eluting stents.
In September, at the World Cardiology Congress in Barcelona, Donald Baim, a cardiologist who is the new chief medical and scientific officer of Boston Scientific, was talking to a reporter when he mentioned disturbing new findings regarding the risk of late thrombosis associated with drug-eluting coronary stents. The revelation fueled a newly ignited controversy. Lauded as a means of preventing restenosis, drug-eluting stents have been implanted in nearly 6 million patients worldwide since they were introduced 3 years ago. The Food and Drug Administration (FDA) responded to the controversy by issuing a statement that drug-eluting stents are “safe and effective . . .
No takes yet. Share an insight, caveat, or question.
Miriam Shuchman (2006) conducted an editorial in Coronary artery disease. Drug-eluting coronary stents was evaluated. Drug-eluting coronary stents are associated with disturbing new findings regarding the risk of late thrombosis, fueling controversy over their safety despite preventing restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: